Hannah Hershoff

Hannah Hershoff M.D., Ph.D. is a neuro-ophthalmologist with over 30 years of clinical and drug development experience. Before joining AiViva Biopharma, Inc., she served as Chief Medical Officer at Longwood Pharmaceuticals, Inc., where she provided vision and leadership to all medical affairs functions and drove the execution of clinical programs, in-licensing, and fund-raising activities. Prior to her medical leadership role at Longwood Pharmaceuticals, Inc., Dr. Hershoff was President and Co-owner of MYAD Consultant Group, where she supervised clinical and development strategy. From 2006 to 2012, she worked at the Novartis Institutes for BioMedical Research as Principal Investigator and the small molecule pipeline Team Leader. She provided oversight for delivering oral and topical molecules to the clinic through line function.

Before her pharmaceutical industry experience, Dr. Hershoff was a senior ophthalmologist, eye surgeon, and physician-in-charge at Zhongshan Eye Hospital, Guangzhou, China. Prior to becoming an ophthalmologist, she practiced as a neurologist at Nanchang First Hospital, China. She is an inventor and author of more than 20 patents and publications in the field of Ophthalmology and Neurology.

Dr. Hershoff received her M.D. from Jiangxi Medical School, China, Ph.D. in Experimental Ophthalmology from Lund University, Sweden, and Post-Doctoral Fellowship from Harvard Medical School. She also received her M.S. in Neurology from Sun Yat-sen University Zhongshan Medical School, China.